AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
67.92
-1.41 (-2.03%)
At close: May 11, 2026, 4:00 PM EDT
67.79
-0.13 (-0.19%)
After-hours: May 11, 2026, 7:03 PM EDT
AnaptysBio Revenue
In the year 2025, AnaptysBio had annual revenue of $234.60M with 157.01% growth. AnaptysBio had revenue of $108.25M in the quarter ending December 31, 2025, with 151.08% growth.
Revenue (ttm)
$234.60M
Revenue Growth
+157.01%
P/S Ratio
8.32
Revenue / Employee
$2,255,798
Employees
104
Market Cap
1.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 234.60M | 143.32M | 157.01% |
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | 5.00M | -5.00M | -50.00% |
| Dec 31, 2017 | 10.00M | -6.68M | -40.06% |
| Dec 31, 2016 | 16.68M | -887.00K | -5.05% |
| Dec 31, 2015 | 17.57M | 1.73M | 10.94% |
| Dec 31, 2014 | 15.84M | 10.36M | 188.86% |
| Dec 31, 2013 | 5.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurinia Pharmaceuticals | 298.30M |
| Syndax Pharmaceuticals | 217.17M |
| Ascentage Pharma Group International | 82.08M |
| Intellia Therapeutics | 66.09M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 52.04M |
| Taysha Gene Therapies | 7.47M |
| Oculis Holding AG | 1.51M |
ANAB News
- 6 hours ago - AnaptysBio appoints Christopher Murphy as CFO - TheFly
- 13 hours ago - Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors - GlobeNewsWire
- 7 days ago - Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - GlobeNewsWire
- 7 days ago - AnaptysBio price target lowered to $93 from $95 at Piper Sandler - TheFly
- 13 days ago - Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - PRNewsWire
- 13 days ago - AnaptysBio price target raised to $85 from $66 at Leerink - TheFly
- 14 days ago - GSK’s TESARO provides update on AnaptysBio litigation - TheFly
- 17 days ago - Delaware court dismisses Tesaro breach of contract claim against AnaptysBio - TheFly